Jazz Pharmaceuticals Provides Update on Phase 2 Trial of Investigational JZP150 in Adult Patients with Post-Traumatic Stress DisorderPRNewsWire • 12/21/23
Jazz Pharmaceuticals' Zanidatamab Promises Growth Amidst Market UndervaluationSeeking Alpha • 12/21/23
Jazz Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare ConferencePRNewsWire • 12/20/23
Jazz Pharmaceuticals Presents Updated Phase 2a Data at SABCS 2023 Showcasing Potential of Zanidatamab in HER2+/HR+ Metastatic Breast CancerPRNewsWire • 12/08/23
Jazz Pharmaceuticals to Present Long-Term and Real-World Data Emphasizing Commitment to Treatment-Resistant Epilepsy at the 2023 American Epilepsy Society Annual MeetingPRNewsWire • 12/01/23
Jazz Pharmaceuticals to Present New Data Highlighting Advancements in Solid Tumors and Rare Blood Cancers at Upcoming Oncology MeetingsPRNewsWire • 11/30/23
Autifony Announces Exclusive Global License and Collaboration Agreement with Jazz Pharmaceuticals on Two Ion Channel Targets for Neurological DisordersBusiness Wire • 11/14/23
Jazz Pharmaceuticals Announces Third Quarter 2023 Financial Results and Updates Financial GuidancePRNewsWire • 11/08/23
Unlocking Q3 Potential of Jazz (JAZZ): Exploring Wall Street Estimates for Key MetricsZacks Investment Research • 11/07/23
Jazz Pharmaceuticals and MD Anderson Announce Five-Year Collaboration to Evaluate Zanidatamab in HER2-Expressing CancersPRNewsWire • 11/07/23
Jazz Pharmaceuticals (JAZZ) Expected to Beat Earnings Estimates: Should You Buy?Zacks Investment Research • 11/01/23
Jazz Pharmaceuticals to Report 2023 Third Quarter Financial Results on November 8, 2023PRNewsWire • 10/25/23
Jazz Pharmaceuticals Presents Data Highlighting the Continued Need for Low-Sodium Treatment Option Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution and Real-World, Evidence-Based Approaches for Individualized Treatment in Adults wPRNewsWire • 10/23/23
Jazz Pharmaceuticals to Present Latest Advancements in Sleep Medicine at World Sleep 2023PRNewsWire • 10/18/23